Correction to: NKX2-1 Activation by SMADS Signaling After Definitive Endoderm Differentiation in Human Embryonic Stem Cell by Li YU,Eggermont K,Vanslembrouch V,and Verfaillie CM. Stem Cells Dev 2013;22;9:1433–1442 DOI:10.1089/scd.2012.0620
Available accessCorrectionFirst published online August, 2020
Correction to: NKX2-1 Activation by SMADS Signaling After Definitive Endoderm Differentiation in Human Embryonic Stem Cell by Li YU,Eggermont K,Vanslembrouch V,and Verfaillie CM. Stem Cells Dev 2013;22;9:1433–1442 DOI:10.1089/scd.2012.0620
The authors of the article entitled, NKX2-1 Activation by SMADS Signaling After Definitive Endoderm Differentiation in Human Embryonic Stem Cell, published in Stem Cells Dev 2013;22;9:1433–1442 wish to correct errors that appeared in Figure 3.
Induction of NKX2-1 expression is Activin-A specific. (A) RT-qPCR measurement and immunostaining for NKX2-1, FOXA2, GATA6, and PAX9 of hESC-H9 cells treated with transforming growth factor (TGF)β1 and TGFβ1+Activin-A between d6 and d8. Data are represented as mean ± SEM from 5 independent experiments (*P < 0.05; **P < 0.01). Scale bar, 100 μm. Percentage FOXA2 positive cells: T5 = 72.3% ± 8.4%, AT5 = 79.5% ± 11.8%; Percentage NKX2-1 positive cells: T5 = 0%; AT5 = 17% ± 11.6% (n = 3). (B) RT-qPCR measurement and immunostaining for NKX2-1, FOXA2, GATA6 and PAX9 of hESC-H9 cells treated with SB431542 and SB431542+Activin-A between d6 and d8. Data are represented as mean ± SEM from 5 independent experiments. Scale bar, 100 μm. Percentage FOXA2 positive cells: SB = 78.1% ± 5%, ASB = 86.9% ± 7.9%; Percentage NKX2-1 positive cells = 0% (n = 2). Color images available online at www.liebertpub.com/scd
Original Figure 3
There is an incorrect entry in the images in Figure 3, SB431542 treated cells stained for NKX2.1 and FOXA2, which show a partial overlap with images in the top row of the SB431542+Activin-A panel, also stained for NKX2.1 and FOX A2.
The images used in Figure 3 were taken from random images acquired from the same well treated with SB431542+Activin-A with possible partial overlap rather than a well treated with SB431542 and a well treated with SB431542+Activin-A.
The authors have supplied a revised Figure 3 as shown next.
Induction of NKX2-1 expression is Activin-A specific. (A) RT-qPCR measurement and immunostaining for NKX2-1, FOXA2, GATA6, and PAX9 of hESC-H9 cells treated with transforming growth factor (TGF)β1 and TGFβ1+Activin-A between d6 and d8. Data are represented as mean ± SEM from 5 independent experiments (*P < 0.05; **P < 0.01). Scale bar, 100 μm. Percentage FOXA2 positive cells: T5 = 72.3% ± 8.4%, AT5 = 79.5% ± 11.8%; Percentage NKX2-1 positive cells: T5 = 0%; AT5 = 17% ± 11.6% (n = 3). (B) RT-qPCR measurement and immunostaining for NKX2-1, FOXA2, GATA6 and PAX9 of hESC-H9 cells treated with SB431542 and SB431542+Activin-A between d6 and d8. Data are represented as mean ± SEM from 5 independent experiments. Scale bar, 100 μm. Percentage FOXA2 positive cells: SB = 78.1% ± 5%, ASB = 86.9% ± 7.9%; Percentage NKX2-1 positive cells = 0% (n = 2). Color images available online at www.liebertpub.com/scd
The online version of this article has been revised to reflect these corrections.
The authors apologize for the mistake; the erroneous image insert did not affect the ultimate conclusion of the manuscript.
